Filing Details

Accession Number:
0001127602-22-005747
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-18 16:10:38
Reporting Period:
2022-02-16
Accepted Time:
2022-02-18 16:10:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1703647 Frequency Therapeutics Inc. FREQ Pharmaceutical Preparations (2834) 472324450
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1842009 Quentin Mccubbin 75 Hayden Ave
Suite 300
Lexington MA 02421
Chief Manufacturing Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-02-16 1,233 $4.43 27,069 No 4 S Direct
Common Stock Disposition 2022-02-17 1,303 $4.20 25,766 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Acquisiton 2022-02-17 150,000 $0.00 150,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
150,000 No 4 A Direct
Footnotes
  1. Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.
  2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.48. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  4. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  5. The restricted stock units will fully vest on July 4, 2023.